If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis

Emma P. Deloughery; Vinay Prasad

doi:10.1007/s11606-018-4498-3

If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis

Emma P. Deloughery, Vinay Prasad

Knight Cancer Institute

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1213-1214
Number of pages	2
Journal	Journal of general internal medicine
Volume	33
Issue number	8
DOIs	https://doi.org/10.1007/s11606-018-4498-3
State	Published - Aug 1 2018

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1007/s11606-018-4498-3

Cite this

@article{cc77eeb840c843ac914dc362785d7982,

title = "If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis",

author = "Deloughery, {Emma P.} and Vinay Prasad",

note = "Funding Information: Funding Information Dr. Prasad is funded by the Laura and John Arnold Foundation.",

year = "2018",

month = aug,

day = "1",

doi = "10.1007/s11606-018-4498-3",

language = "English (US)",

volume = "33",

pages = "1213--1214",

journal = "Journal of general internal medicine",

issn = "0884-8734",

publisher = "Springer New York",

number = "8",

}

TY - JOUR

T1 - If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis

AU - Deloughery, Emma P.

AU - Prasad, Vinay

N1 - Funding Information: Funding Information Dr. Prasad is funded by the Laura and John Arnold Foundation.

PY - 2018/8/1

Y1 - 2018/8/1

UR - http://www.scopus.com/inward/record.url?scp=85047978250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047978250&partnerID=8YFLogxK

U2 - 10.1007/s11606-018-4498-3

DO - 10.1007/s11606-018-4498-3

M3 - Editorial

AN - SCOPUS:85047978250

SN - 0884-8734

VL - 33

SP - 1213

EP - 1214

JO - Journal of general internal medicine

JF - Journal of general internal medicine

IS - 8

ER -

If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this